Using a selective Chk1 inhibitor LY2603618, currently undergoing phase II clinical trial48, we have observed increased elimination of tumor cells lacking de novo pyrimidine synthesis, especially those with p53-deficient status. Here, CHEK1 is linked to neoplasm.